Could an open-access database speed up drug development? Could an open-access database speed up drug development? Capitol Connection October 6, 2014 A recent study finds a significant logjam in the development of new drugs at the discovery and early preclinical phases. Could the creation of an open-source translational research database help solve the problem? NIH and NSF team up to accelerate bench-to-marketplace transitions Capitol Connection July 1, 2014 The National Institutes of Health (NIH) and National Science Foundation (NSF) are teaming up to help researchers commercialize new biomedical discoveries. Researchers who are part of the new I-Corps at NIH pilot program will participate in a nine-week boot camp where they will meet with business experts and potential customers. I-Corps at NIH is the newest outgrowth of the NSF’s Innovation Corps (I-Corps) private-public partnership program, which helps commercialize selected federally funded research projects. NIH says its time to start using female animals too NIH says it's time to start using female animals too Capitol Connection June 24, 2014 According to data recently released by the Food and Drug Administration, women report more adverse drug reactions than do men. While this finding could be due to greater reporting of side effects by women, it also may have something to do with the longstanding bias against using female animals in preclinical medical research. Conference at the intersection of genomics and immunology Conference will bring together scientists at the intersection of genomics and immunology In Depth June 5, 2014 At the intersection of two important medical fields—immunology and genomics—lies immunogenomics, an area of research that explores the ways in which the human genome interacts with disease. This approach already has helped doctors diagnose a form of cancer a year earlier than previously possible. Kevin Healy Kevin Healy goes small to make a big leap in drug-testing platform Member Spotlight May 27, 2014 Sometimes, going small can make a tremendous difference. That's the theory, at least, behind AAAS Fellow Kevin Healy’s bioengineering innovations. The University of California, Berkeley, bioengineering professor is developing a drug-testing tool to make the discovery of new medicines faster and cheaper. It has several names, but they all reveal its diminutive scale. Neuroscientists have a nested data problem (and they're not alone) Driving Force May 1, 2014 Neuroscientists have an ever-increasing array of high-tech techniques at their disposal. These tools allow researchers to make increasingly detailed measurements from individual neurons, and even components, of individual neurons. Unfortunately, they also have led to a statistical problem: the improper analysis of nested data. According to a recent report, 53 percent of molecular, cellular and developmental neuroscience papers published in five prominent journals contained nested data that call into question the true strength of these papers’ findings. FDA considers allowing embryos with three genetic parents Capitol Connection March 27, 2014 Each year, around 4,000 babies are born with inherited mitochondrial diseases in the United States. Problems can include blindness, epilepsy, movement disorders, liver failure, necrotizing brain lesions, and other serious maladies.The Food and Drug Administration (FDA) is now considering whether to allow mitochondria replacement to be used in humans to prevent these diseases. Anne Stone traces evolution of tuberculosis and its hosts Anne Stone traces evolution of tuberculosis and its hosts Member Spotlight February 28, 2014 Obsessed with the way species live and evolve together, anthropological geneticist Anne Stone wants to know “How close are we to our closest relative?” and “Are we a reservoir for pathogens?” Is YODA wise enough to navigate a global public-private data project? Is YODA wise enough to navigate a global public-private data project? Capitol Connection February 19, 2014 Johnson & Johnson recently announced that its subsidiary, Janssen Research and Development, LLC, will partner with the Yale School of Medicine’s Open Data Access (YODA) project to share anonymized clinical trial data. The project seeks to provide “rigorous and objective evaluation of clinical trial data to ensure that patients and physicians possess all necessary information about a drug or device when making treatment decisions.” Janssen is the first company to partner with the project. First successful bone marrow transplant patient surviving and thriving at 60 In Depth February 10, 2014 Editor’s note: This interview is a side story for Thank Uncle Sam for life-saving bone marrow transplants, a look at how federal funding has advanced important discoveries.